-
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
D'Haens, G. R., löwenberg, M., Baert, F., Bossuyt, P., Molnár, T., Hoentjen, F., Clasquin, E., Gecse, K. B., Hulshoff, M. S., de Hertogh, G., Lenfant, M., Oldenburg, L. & Vermeire, S. V., 1 Jan 2026, In: lancet. Gastroenterology & hepatology. 11, 1, p. 12-21Research output: Contribution to journal › Article › Academic › peer-review
-
Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study
Joustra, V. W., Li Yim, A. Y. F., Henneman, P., Hageman, I., de Waard, T., Levin, E., Noble, A. J., Chapman, T. P., Mol, F., van Zon, S., Lee, D., McGregor, C. G. C., Hulshoff, M. S., Satsangi, J. J., de Jonge, W. J., D'Haens, G. R. & EPIC-CD Consortium, Sept 2025, In: The Lancet Gastroenterology and Hepatology. 10, 9, p. 818-830 13 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
D'Haens, G., Taxonera, C., Lopez-Sanroman, A., Nos, P., Danese, S., Armuzzi, A., Roblin, X., Peyrin-Biroulet, L., West, R., Mares, W. G. N., Duijvestein, M., Gecse, K. B., Feagan, B. G., Zou, G., Hulshoff, M. S., Mookhoek, A., Oldenburg, L., Clasquin, E., Bouhnik, Y. & Laharie, D., 1 Jan 2025, In: The Lancet Gastroenterology and Hepatology. 10, 1, p. 26-33 8 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
